Sunitin 50 Capsule contains Sunitinib 50 mg, a targeted anticancer medicine used in the treatment of several advanced and metastatic cancers. It helps inhibit tumor growth and reduce the formation of new blood vessels that supply nutrients and oxygen to cancer cells. By targeting multiple signaling pathways involved in cancer progression, the medicine supports effective disease control and forms an important part of modern oncology treatment strategies. The capsule is prescribed under the supervision of oncology specialists for long-term cancer management.

Sunitinib belongs to the class of multikinase inhibitors and works by blocking various receptor tyrosine kinases that play a critical role in tumor growth, angiogenesis, and cancer cell survival. By interfering with these pathways, it helps slow the progression of cancer and limit the spread of malignant cells. Its targeted mechanism of action has made it an established therapeutic option in the management of several difficult-to-treat cancers.

The capsule is commonly prescribed for renal cell carcinoma, gastrointestinal stromal tumors (GIST), pancreatic neuroendocrine tumors, and other malignancies as determined by an oncology specialist. Depending on the patient's condition and treatment plan, it may be used as a single-agent therapy or as part of a broader cancer management approach. Regular monitoring during treatment is essential to assess therapeutic response and manage potential adverse effects effectively.

With the increasing use of targeted cancer therapies and personalized oncology treatment approaches, Sunitin 50 Capsule maintains strong demand in the oncology segment. Its proven clinical efficacy, broad therapeutic applications, and widespread acceptance among oncology professionals contribute to consistent market growth. The product offers valuable business opportunities and sustainable long-term potential for retailers and distributors operating within the oncology pharmaceutical sector.

Sunitin 50 Capsule may cause fatigue, nausea, vomiting, diarrhea, decreased appetite, abdominal discomfort, mouth ulcers, skin discoloration, hand-foot syndrome, and hypertension. Serious adverse effects such as liver dysfunction, cardiac complications, bleeding events, thyroid abnormalities, and kidney function changes may occur and require close medical supervision.

Sunitin 50 Capsule is indicated for the treatment of renal cell carcinoma, gastrointestinal stromal tumors (GIST), pancreatic neuroendocrine tumors, and other cancers as determined by an oncology specialist. It helps inhibit tumor growth, reduce angiogenesis, and support comprehensive cancer management.

This medication should be used only under the supervision of a qualified healthcare professional experienced in oncology treatment. Regular monitoring of blood pressure, liver function, kidney function, thyroid function, blood counts, and overall patient health is essential throughout therapy. Patients should promptly report unusual bleeding, chest pain, severe fatigue, breathing difficulties, or any other concerning symptoms. Treatment should always be individualized according to the patient's condition and clinical response.

Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the capsules in their original packaging and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of tampering.